$CYTK
CYTOKINETICS INC

2023 Q1 Form 10-K Financial Statement

#000095017023005515 Filed on March 01, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $4.613M $1.957M $94.59M
YoY Change 301.83% -96.48% 34.3%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $49.67M $53.97M $178.0M
YoY Change 50.18% 59.64% 83.85%
% of Gross Profit
Research & Development $79.42M $75.02M $240.8M
YoY Change 72.9% 72.46% 50.57%
% of Gross Profit
Depreciation & Amortization $1.848M $1.658M $5.814M
YoY Change 37.81% 125.89% 155.45%
% of Gross Profit
Operating Expenses $129.1M $129.0M $418.8M
YoY Change 63.39% 66.86% 63.12%
Operating Profit -$124.5M -$324.2M
YoY Change 59.87% 74.01%
Interest Expense $6.961M -$10.35M $19.41M
YoY Change 153.5% 16.74% 18.09%
% of Operating Profit
Other Income/Expense, Net $6.425M $11.34M
YoY Change 1448.19% 3326.59%
Pretax Income -$131.3M -$137.4M -$389.0M
YoY Change 46.78% 349.39% 80.65%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$131.3M -$137.4M -$389.0M
YoY Change 46.79% 349.39% 80.68%
Net Earnings / Revenue -2846.3% -7019.93% -411.26%
Basic Earnings Per Share -$1.38 -$4.33
Diluted Earnings Per Share -$1.38 -$1.45 -$4.33
COMMON SHARES
Basic Shares Outstanding 95.16M 94.63M 89.83K
Diluted Shares Outstanding 95.16K 89.83K

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $664.0M $782.6M $782.6M
YoY Change 9.03% 65.93% 65.93%
Cash & Equivalents $101.6M $65.58M $65.58M
Short-Term Investments $562.3M $717.0M $717.0M
Other Short-Term Assets $15.66M $12.46M $12.46M
YoY Change 84.33% 2.02% 2.02%
Inventory
Prepaid Expenses
Receivables $1.006M $147.0K $147.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $680.6M $795.2M $795.2M
YoY Change 9.16% 48.45% 48.45%
LONG-TERM ASSETS
Property, Plant & Equipment $78.86M $80.45M $163.2M
YoY Change 4.12% 9.8% 11.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $40.41M $46.71M $46.71M
YoY Change -47.58% -69.28% -69.28%
Other Assets $8.119M $9.691M $9.691M
YoY Change 11.86% 34.82% 34.82%
Total Long-Term Assets $209.2M $219.6M $219.6M
YoY Change -10.12% -28.16% -28.16%
TOTAL ASSETS
Total Short-Term Assets $680.6M $795.2M $795.2M
Total Long-Term Assets $209.2M $219.6M $219.6M
Total Assets $889.8M $1.015B $1.015B
YoY Change 3.92% 20.62% 20.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $17.36M $25.61M $25.61M
YoY Change -12.5% 21.45% 21.45%
Accrued Expenses $35.63M $44.10M $56.93M
YoY Change 20.88% 28.3% 15.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.000M $1.000M
YoY Change 100.0%
Total Short-Term Liabilities $75.22M $84.62M $84.62M
YoY Change 12.53% 17.75% 17.75%
LONG-TERM LIABILITIES
Long-Term Debt $64.11M $63.81M $610.6M
YoY Change 4.81% 34.71% 325.11%
Other Long-Term Liabilities $837.0K $1.044M $427.4M
YoY Change -73.93% -76.58% 11.91%
Total Long-Term Liabilities $64.95M $64.85M $1.038B
YoY Change 0.89% 25.14% 97.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $75.22M $84.62M $84.62M
Total Long-Term Liabilities $64.95M $64.85M $1.038B
Total Liabilities $1.119B $1.123B $1.123B
YoY Change 51.2% 87.91% 87.91%
SHAREHOLDERS EQUITY
Retained Earnings -$1.700B -$1.600B
YoY Change 42.02% 32.49%
Common Stock $1.490B $1.482B
YoY Change 5.94% 2.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$229.0M -$107.9M -$107.9M
YoY Change
Total Liabilities & Shareholders Equity $889.8M $1.015B $1.015B
YoY Change 3.92% 20.62% 20.62%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$131.3M -$137.4M -$389.0M
YoY Change 46.79% 349.39% 80.68%
Depreciation, Depletion And Amortization $1.848M $1.658M $5.814M
YoY Change 37.81% 125.89% 155.45%
Cash From Operating Activities -$122.3M -$98.19M -$299.5M
YoY Change 356.16% 119.48% 110.18%
INVESTING ACTIVITIES
Capital Expenditures $402.0K $3.205M $11.34M
YoY Change -57.32% -118.05% -123.19%
Acquisitions
YoY Change
Other Investing Activities $165.9M $32.45M -$250.8M
YoY Change -361.93% -50.14% 153.58%
Cash From Investing Activities $165.5M $29.25M -$262.1M
YoY Change -357.47% -38.21% 77.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $0.00 $47.65M
YoY Change -100.0%
Cash From Financing Activities -7.177M 29.89M 516.2M
YoY Change -107.65% 53.21% 61.31%
NET CHANGE
Cash From Operating Activities -122.3M -98.19M -299.5M
Cash From Investing Activities 165.5M 29.25M -262.1M
Cash From Financing Activities -7.177M 29.89M 516.2M
Net Change In Cash 36.03M -39.06M -45.48M
YoY Change 1207.47% -276.69% -253.24%
FREE CASH FLOW
Cash From Operating Activities -$122.3M -$98.19M -$299.5M
Capital Expenditures $402.0K $3.205M $11.34M
Free Cash Flow -$122.7M -$101.4M -$310.8M
YoY Change 342.12% 275.77% 231.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001061983
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
CY2022Q4 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilities
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
000-50633
CY2022 dei Entity Registrant Name
EntityRegistrantName
CYTOKINETICS, INCORPORATED
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3291317
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
350 Oyster Point Boulevard
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2022 dei City Area Code
CityAreaCode
650
CY2022 dei Local Phone Number
LocalPhoneNumber
624-3000
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2022 dei Trading Symbol
TradingSymbol
CYTK
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
false
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
2000000000.0
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
95161391
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
San Mateo, California
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65582000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112666000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
716995000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
358972000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
147000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
51819000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12462000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12215000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
795186000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
535672000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
46708000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
152050000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
80453000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
73271000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
82737000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
73138000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9691000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7188000
CY2022Q4 us-gaap Assets
Assets
1014775000
CY2021Q4 us-gaap Assets
Assets
841319000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
25611000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
21087000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
44096000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34370000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12829000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
14863000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2081000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1540000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
84617000
CY2021Q4 cytk Convertible Notes Net
ConvertibleNotesNet
95471000
CY2022Q4 cytk Liabilities Related To Revenue Participation Right Purchase Agreement Net
LiabilitiesRelatedToRevenueParticipationRightPurchaseAgreementNet
300501000
CY2021Q4 cytk Liabilities Related To Revenue Participation Right Purchase Agreement Net
LiabilitiesRelatedToRevenueParticipationRightPurchaseAgreementNet
179072000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
71860000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
63810000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
47367000
CY2022Q4 cytk Convertible Notes Net
ConvertibleNotesNet
545808000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
87000000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
126895000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
112229000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1044000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4457000
CY2022Q4 us-gaap Liabilities
Liabilities
1122675000
CY2021Q4 us-gaap Liabilities
Liabilities
597456000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
163000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
163000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
94833975
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
94833975
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
84799542
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
84799542
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
94000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
84000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1481590000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1452268000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3590000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-869000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1585994000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1207620000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-107900000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
243863000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1014775000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
841319000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94588000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
70428000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55828000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
240813000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
159938000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96951000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
177977000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
96803000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-93943000
CY2022 us-gaap Interest Expense
InterestExpense
19414000
CY2021 us-gaap Interest Expense
InterestExpense
16440000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
52820000
CY2020 cytk Gain Loss On Extinguishment And Repurchase Of Debt Instrument
GainLossOnExtinguishmentAndRepurchaseOfDebtInstrument
0
CY2020 us-gaap Interest Expense
InterestExpense
15963000
CY2022 us-gaap Operating Expenses
OperatingExpenses
418790000
CY2021 us-gaap Operating Expenses
OperatingExpenses
256741000
CY2020 us-gaap Operating Expenses
OperatingExpenses
149771000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-324202000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-186313000
CY2022 cytk Gain Loss On Extinguishment And Repurchase Of Debt Instrument
GainLossOnExtinguishmentAndRepurchaseOfDebtInstrument
-24939000
CY2021 cytk Gain Loss On Extinguishment And Repurchase Of Debt Instrument
GainLossOnExtinguishmentAndRepurchaseOfDebtInstrument
0
CY2022 cytk Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
31742000
CY2021 cytk Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
12892000
CY2020 cytk Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
22713000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11342000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
331000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5329000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-388955000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-215314000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-127290000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.33
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.33
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.80
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.80
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.97
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.97
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
89825
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
89825
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76886
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76886
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64524
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64524
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2721000
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1018000
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-530000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-391676000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-216332000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-127820000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-10937000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7611000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0
CY2020 cytk Adjustment To Additional Paid In Capital To Section16 B Claim Settlement
AdjustmentToAdditionalPaidInCapitalToSection16BClaimSettlement
2151000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
188883000
CY2020 cytk Stock Issue During Period Private Placement Value
StockIssueDuringPeriodPrivatePlacementValue
36437000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1509000
CY2020 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2255000
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
184000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17620000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-530000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-127290000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
113383000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11020000
CY2021 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
4449000
CY2021 cytk Net Share Settlements
NetShareSettlements
-418000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
296905000
CY2021 cytk Stock Issue During Period Private Placement Value
StockIssueDuringPeriodPrivatePlacementValue
15144000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1778000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26832000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1018000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-215314000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
243863000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14316000
CY2022 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2022 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
9602000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3227000
CY2022 cytk Stock Issued During Period Value Inducted Conversion Of Convertible Notes
StockIssuedDuringPeriodValueInductedConversionOfConvertibleNotes
-3378000
CY2022 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0
CY2022 cytk Adjustments To Additional Paid In Capital Capped Call Options Associated With Convertible Notes
AdjustmentsToAdditionalPaidInCapitalCappedCallOptionsAssociatedWithConvertibleNotes
-26392000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
47853000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2721000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-388955000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-107900000
CY2022 us-gaap Profit Loss
ProfitLoss
-388955000
CY2021 us-gaap Profit Loss
ProfitLoss
-215314000
CY2020 us-gaap Profit Loss
ProfitLoss
-127290000
CY2022 cytk Non Cash Interest Expense On Liabilities Related To Revenue Participant Right Purchase Agreement
NonCashInterestExpenseOnLiabilitiesRelatedToRevenueParticipantRightPurchaseAgreement
31858000
CY2021 cytk Non Cash Interest Expense On Liabilities Related To Revenue Participant Right Purchase Agreement
NonCashInterestExpenseOnLiabilitiesRelatedToRevenueParticipantRightPurchaseAgreement
13004000
CY2020 cytk Non Cash Interest Expense On Liabilities Related To Revenue Participant Right Purchase Agreement
NonCashInterestExpenseOnLiabilitiesRelatedToRevenueParticipantRightPurchaseAgreement
22792000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
47853000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
26832000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
17620000
CY2022 cytk Non Cash Lease Expense
NonCashLeaseExpense
2585000
CY2021 cytk Non Cash Lease Expense
NonCashLeaseExpense
7361000
CY2020 cytk Non Cash Lease Expense
NonCashLeaseExpense
4221000
CY2022 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2021 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
2844000
CY2020 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5814000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2276000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1831000
CY2022 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-107000
CY2021 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0
CY2020 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
573000
CY2022 cytk Interest Receivable And Amortization On Investments
InterestReceivableAndAmortizationOnInvestments
-4710000
CY2021 cytk Interest Receivable And Amortization On Investments
InterestReceivableAndAmortizationOnInvestments
4894000
CY2020 cytk Interest Receivable And Amortization On Investments
InterestReceivableAndAmortizationOnInvestments
-1194000
CY2022 us-gaap Paid In Kind Interest
PaidInKindInterest
5697000
CY2021 us-gaap Paid In Kind Interest
PaidInKindInterest
7125000
CY2020 us-gaap Paid In Kind Interest
PaidInKindInterest
6640000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2693000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2022 us-gaap Gain Loss On Repurchase Of Debt Instrument
GainLossOnRepurchaseOfDebtInstrument
-22246000
CY2021 us-gaap Gain Loss On Repurchase Of Debt Instrument
GainLossOnRepurchaseOfDebtInstrument
0
CY2022 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
4524000
CY2021 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1055000
CY2020 us-gaap Gain Loss On Repurchase Of Debt Instrument
GainLossOnRepurchaseOfDebtInstrument
0
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-56672000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
47399000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-743000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7414000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7381000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5162000
CY2020 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-110000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
10844000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
15060000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
7117000
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-87000000
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2020 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
87000000
CY2022 cytk Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
1728000
CY2021 cytk Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
43472000
CY2020 cytk Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4692000
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-4058000
CY2021 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
3649000
CY2020 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-299516000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-142522000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
8943000
CY2022 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
855393000
CY2021 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
525042000
CY2020 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
435825000
CY2022 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
604594000
CY2021 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
422837000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
247301000
CY2022 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2021 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
3300000
CY2020 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
3061000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11335000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48872000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11052000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-262134000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-147777000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-196515000
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
944000
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
CY2020 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
CY2022 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
47651000
CY2021 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
CY2020 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
CY2022 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
2409000
CY2021 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
0
CY2020 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
0
CY2022 cytk Repayment Of Convertible Debts
RepaymentOfConvertibleDebts
140330000
CY2021 cytk Repayment Of Convertible Debts
RepaymentOfConvertibleDebts
0
CY2020 cytk Repayment Of Convertible Debts
RepaymentOfConvertibleDebts
0
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
523586000
CY2021 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2020 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2022 cytk Proceeds From Issuance Of Underwritten Public Offering Of Common Stock Net
ProceedsFromIssuanceOfUnderwrittenPublicOfferingOfCommonStockNet
0
CY2021 cytk Proceeds From Issuance Of Underwritten Public Offering Of Common Stock Net
ProceedsFromIssuanceOfUnderwrittenPublicOfferingOfCommonStockNet
296905000
CY2020 cytk Proceeds From Issuance Of Underwritten Public Offering Of Common Stock Net
ProceedsFromIssuanceOfUnderwrittenPublicOfferingOfCommonStockNet
188883000
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2021 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
15144000
CY2020 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
36225000
CY2022 cytk Proceeds From2022 Rpi Transactionsne
ProceedsFrom2022RPITransactionsne
149581000
CY2021 cytk Proceeds From2022 Rpi Transactionsne
ProceedsFrom2022RPITransactionsne
0
CY2020 cytk Proceeds From2022 Rpi Transactionsne
ProceedsFrom2022RPITransactionsne
0
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
17543000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
12380000
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
9120000
CY2022 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
9602000
CY2021 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4449000
CY2020 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2255000
CY2022 cytk Proceeds From Claims Settlements
ProceedsFromClaimsSettlements
0
CY2021 cytk Proceeds From Claims Settlements
ProceedsFromClaimsSettlements
0
CY2020 cytk Proceeds From Claims Settlements
ProceedsFromClaimsSettlements
2151000
CY2022 cytk Payment For Purchase Of Capped Call Options Associated With Convertible Notes
PaymentForPurchaseOfCappedCallOptionsAssociatedWithConvertibleNotes
-26392000
CY2021 cytk Payment For Purchase Of Capped Call Options Associated With Convertible Notes
PaymentForPurchaseOfCappedCallOptionsAssociatedWithConvertibleNotes
0
CY2020 cytk Payment For Purchase Of Capped Call Options Associated With Convertible Notes
PaymentForPurchaseOfCappedCallOptionsAssociatedWithConvertibleNotes
0
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
516166000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
319980000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
234124000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-45484000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
29681000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
46552000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
112666000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
82985000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36433000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
67182000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
112666000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
82985000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
15165000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
9175000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
9620000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
10904000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
80395000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1106000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
1055000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
1294000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
621000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
11982000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2022 cytk Fair Value Of Stock Issued For Convertible Note
FairValueOfStockIssuedForConvertibleNote
317123000
CY2021 cytk Fair Value Of Stock Issued For Convertible Note
FairValueOfStockIssuedForConvertibleNote
0
CY2020 cytk Fair Value Of Stock Issued For Convertible Note
FairValueOfStockIssuedForConvertibleNote
0
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1600000000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-389000000.0
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-299500000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
829300000
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
623700000
CY2022 cytk Cash Requirements Term
CashRequirementsTerm
P12M
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. We evaluate our estimates on an ongoing basis. We base our estimates on our historical experience and also on assumptions that we believe are reasonable; however, actual results could significantly differ from those estimates.</span></p>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject us to concentrations of risk consist principally of cash, cash equivalents, restricted cash equivalents, investments, and accounts receivable.</span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our cash, cash equivalents, restricted cash equivalents, and investments held with large financial institutions in the United States and deposits may exceed the Federal Deposit Insurance Corporation’s insurance limit.</span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our exposure to credit risk associated with non-payment includes, but is not limited to, Astellas Pharma Inc. for co-funding one-third of the out-of-pocket clinical development costs which may be incurred in connection with Cytokinetics’ Phase 3 clinical trial, COURAGE-ALS, of reldesemtiv in ALS up to a maximum contribution by Astellas of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, to our strategic partner in China and Taiwan, Ji Xing</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and RPI ICAV, to whom we sold a revenue interest in our net sales of pharmaceutical products containing aficamten under the RP Aficamten RPA, as further described in Note 11 below.</span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Drug candidates we develop may require approvals or clearances from the FDA or other regulatory agencies prior to commercial sales. There can be no assurance that our drug candidates will receive any of the required approvals or clearances. If we were to be denied approval, or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.</span></p>
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65582000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112666000
CY2022Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
1600000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67182000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
112666000
CY2022Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
1600000
CY2021Q4 us-gaap Convertible Debt
ConvertibleDebt
95471000
CY2022Q1 us-gaap Convertible Debt
ConvertibleDebt
134366000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1452268000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1402792000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1207620000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1197039000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25404000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27519000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26362000
CY2021Q3 cytk Milestone Payments Received Under Arrangements
MilestonePaymentsReceivedUnderArrangements
5000000.0
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
825593000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
626959000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
11400000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000000.0
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
5300000
CY2022 us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
0
CY2021 us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
0
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
97547000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
89460000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
17094000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16189000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
80453000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
73271000
CY2022 us-gaap Depreciation
Depreciation
5800000
CY2021 us-gaap Depreciation
Depreciation
2300000
CY2020 us-gaap Depreciation
Depreciation
1800000
CY2022Q4 cytk Accrued Clinical And Preclinical Costs Current
AccruedClinicalAndPreclinicalCostsCurrent
16105000
CY2021Q4 cytk Accrued Clinical And Preclinical Costs Current
AccruedClinicalAndPreclinicalCostsCurrent
13872000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21767000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14930000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6224000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5568000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
44096000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34370000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
649563000
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1800000
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1100000
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
900000
CY2022Q1 cytk Arrangement Consideration Of Debt Transaction
ArrangementConsiderationOfDebtTransaction
150000000
CY2022 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
484400000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
10295000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
19745000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
19745000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
40878000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
558900000
CY2022Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
88431000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
561132000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
15324000
CY2022Q4 cytk Convertible Notes Net
ConvertibleNotesNet
545808000
CY2019Q4 cytk Capped Call Transactions Cap Price
CappedCallTransactionsCapPrice
14.07
CY2019Q4 cytk Capped Call Premium Percentage Of Sale Price Of Common Stock
CappedCallPremiumPercentageOfSalePriceOfCommonStock
0.70
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7759012
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.59
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
1944562
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
15.59
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.27
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
234054
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
16.06
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8501949
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.02
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
2513350
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
22.43
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.01
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
296146
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
14.56
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9372959
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.35
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
3424150
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
39.79
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.13
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
415675
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
28.94
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10992403
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
22.13
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
261900000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6153725
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.21
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M6D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
200700000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
47853000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26832000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17620000
CY2020Q1 cytk Proceeds From Claims Settlements
ProceedsFromClaimsSettlements
2200000
CY2021 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
2800000
CY2022Q4 us-gaap Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
P3Y
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
13465000
CY2022Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
990000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
18738000
CY2022Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
990000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
19563000
CY2022Q4 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
204000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
20180000
CY2022Q4 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
20514000
CY2022Q4 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
0
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
130719000
CY2022Q4 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
0
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
223179000
CY2022Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
2184000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
83455000
CY2022Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
183000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
139724000
CY2022Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
2001000
CY2022 cytk Operating And Finance Lease Expense
OperatingAndFinanceLeaseExpense
21600000
CY2021 cytk Operating And Finance Lease Expense
OperatingAndFinanceLeaseExpense
23100000
CY2020 cytk Operating And Finance Lease Expense
OperatingAndFinanceLeaseExpense
5700000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.01
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.01
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.01
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.02
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.04
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.03
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.03
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.26
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.24
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.23
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.02
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.02
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.01
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.02
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.01
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.01
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
202459000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
181977000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
98292000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
77366000
CY2022Q4 cytk Deferred Tax Assets Liability Related To Sale Of Future Royalties
DeferredTaxAssetsLiabilityRelatedToSaleOfFutureRoyalties
68366000
CY2021Q4 cytk Deferred Tax Assets Liability Related To Sale Of Future Royalties
DeferredTaxAssetsLiabilityRelatedToSaleOfFutureRoyalties
38302000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
23950000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
15409000
CY2022Q4 cytk Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
48047000
CY2021Q4 cytk Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
1115000
CY2022Q4 cytk Deferred Tax Assets Long Term Lease Liability
DeferredTaxAssetsLongTermLeaseLiability
28901000
CY2021Q4 cytk Deferred Tax Assets Long Term Lease Liability
DeferredTaxAssetsLongTermLeaseLiability
26223000
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
0
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
18608000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
470015000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
359000000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
7909000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
7664000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
18192000
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
15643000
CY2022Q4 us-gaap Deferred Tax Liabilities Financing Arrangements
DeferredTaxLiabilitiesFinancingArrangements
0
CY2021Q4 us-gaap Deferred Tax Liabilities Financing Arrangements
DeferredTaxLiabilitiesFinancingArrangements
8296000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
26101000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
31603000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
443914000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
327397000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
116500000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
52600000
CY2022 cytk Research And Development Federal Tax Credit Carryforwards Expiration Date Year
ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear
2022
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11295000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10522000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9922000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
4438000
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
1804000
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
29000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
3000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
4426000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
802000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
603000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
18355000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11295000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10522000
CY2022Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
17700000
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
10300000
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
9600000

Files In Submission

Name View Source Status
0000950170-23-005515-index-headers.html Edgar Link pending
0000950170-23-005515-index.html Edgar Link pending
0000950170-23-005515.txt Edgar Link pending
0000950170-23-005515-xbrl.zip Edgar Link pending
cytk-20221231.htm Edgar Link pending
cytk-20221231.xsd Edgar Link pending
cytk-ex10_11.htm Edgar Link pending
cytk-ex10_12.htm Edgar Link pending
cytk-ex10_13.htm Edgar Link pending
cytk-ex10_14.htm Edgar Link pending
cytk-ex10_15.htm Edgar Link pending
cytk-ex10_16.htm Edgar Link pending
cytk-ex10_17.htm Edgar Link pending
cytk-20221231_cal.xml Edgar Link unprocessable
cytk-20221231_def.xml Edgar Link unprocessable
cytk-20221231_lab.xml Edgar Link unprocessable
cytk-20221231_pre.xml Edgar Link unprocessable
cytk-20221231_htm.xml Edgar Link completed
cytk-ex10_22.htm Edgar Link pending
cytk-ex10_23.htm Edgar Link pending
cytk-ex10_28.htm Edgar Link pending
cytk-ex10_5.htm Edgar Link pending
cytk-ex10_9.htm Edgar Link pending
cytk-ex23_1.htm Edgar Link pending
cytk-ex31_1.htm Edgar Link pending
cytk-ex31_2.htm Edgar Link pending
cytk-ex31_3.htm Edgar Link pending
cytk-ex32_1.htm Edgar Link pending
cytk-ex4_6.htm Edgar Link pending
cytk-ex4_9.htm Edgar Link pending
cytk-ex5_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img114166951_0.jpg Edgar Link pending
img191550080_0.jpg Edgar Link pending
img192473601_0.jpg Edgar Link pending
img193397122_0.jpg Edgar Link pending
img194320643_0.jpg Edgar Link pending
img195244164_0.jpg Edgar Link pending
img196167685_0.jpg Edgar Link pending
img197091206_0.jpg Edgar Link pending
img256722589_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable